Search NLS News

The partnership will include access to the scientific, clinical and drug development expertise of the Leukemia & Lymphoma Society (LLS) as well as a strategic capital equity investment from LLS TAP of 3 million USD. The acceleration program aims to advance the BioInvent International’s program to treat blood cancers, states the company in a press […]

IRLAB Therapeutics has announced the results from the Phase IIb study of mesdopetam in people with Parkinson’s disease levodopa-induced dyskinesias (PD-LIDs). The primary endpoint, change in daily hours of ON-time without troublesome dyskinesia, as assessed with patient diaries, did not reach statistical significance by mesdopetam compared to placebo. “Unfortunately, the primary endpoint to increase “good […]

AlzeCure Pharma has chosen a candidate drug (CD) and started the preclinical development phase with the company’s preventive and disease-modifying candidate drug Alzstatin ACD680. ACD680 is being developed within AlzeCure’s Alzstatin platform, with the aim of developing a preventive and disease-modifying drug for the early treatment of Alzheimer’s disease. In the project, a CD has […]

Karolinska University Hospital’s cancer department has signed an agreement with Bristol Myers Squibb to start an oncology and hematology research collaboration focusing on advancing research and generating data with an aim to deliver innovative therapies for patients. The organizations will centralize the work through a steering committee consisting of experts from both organizations to discuss […]

IRLAB Therapeutics has announced that a drug candidate has been nominated from the P003 research project. The drug candidate, IRL1117, will be developed as a once-daily oral treatment for the hallmark symptoms of Parkinson’s without inducing the troublesome complications caused by today’s mainstay anti-Parkinson’s levodopa treatments, states the company. Initiation of development towards clinical studies […]

Airsupra (albuterol/budesonide), formerly known as PT027, has been approved in the US for the as-needed treatment or prevention of bronchoconstriction and to reduce the risk of exacerbations in people with asthma aged 18 years and older. “With patients experiencing more than 10 million asthma exacerbations each year in the US and uncontrolled asthma expected to cost […]

He joined Industrifonden in March 2022, after 25 years of business development within both life sciences and tech. What are you most looking forward to doing/working with in your new role? “I look forward to partnering with exceptional entrepreneurs to build successful companies from unique Nordic innovations. Industrifonden has an evergreen structure, which is a […]

Johan Färnstrand has been appointed new Director General of the trade association for the research-based pharmaceutical industry in Sweden. Färnstrand will start his new position on March 1st, succeeding Anders Blanck who leaves Lif at his own request after 11 years as Director General. Johan Färnstrand Johan Färnstrand has during the last couple of years […]

The Series B financing round of HVR Cardio was led by Finnish Innovestor Life Science Fund and Tesi. The Finnish cardiovascular device company HVR Cardio is developing a catheter-based solution CathHELIX, which makes it possible to repair the fault without the need for demanding open-heart surgery. The solution has already been granted Breakthrough Device Designation status by the […]

What are the secret ingredients for successful company growth within life sciences? What lessons can we learn from the journeys, progress, setbacks and challenges of other Nordic companies? What perspectives and advice can the region’s investors and business advisors provide? The pandemic’s impact on life and businesses is slowly coming to an end, at least […]